Cargando…

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications

BACKGROUND: There is a need to better characterise cell-based therapies in preclinical models to help facilitate their translation to humans. Long-term high-resolution tracking of the cells in vivo is often impossible due to unreliable methods. Radiolabelling of cells has the advantage of being able...

Descripción completa

Detalles Bibliográficos
Autores principales: Friberger, Ida, Jussing, Emma, Han, Jinming, Goos, Jeroen A. C. M., Siikanen, Jonathan, Kaipe, Helen, Lambert, Mélanie, Harris, Robert A., Samén, Erik, Carlsten, Mattias, Holmin, Staffan, Tran, Thuy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578071/
https://www.ncbi.nlm.nih.gov/pubmed/34231103
http://dx.doi.org/10.1007/s11307-021-01622-z
_version_ 1784596198056787968
author Friberger, Ida
Jussing, Emma
Han, Jinming
Goos, Jeroen A. C. M.
Siikanen, Jonathan
Kaipe, Helen
Lambert, Mélanie
Harris, Robert A.
Samén, Erik
Carlsten, Mattias
Holmin, Staffan
Tran, Thuy A.
author_facet Friberger, Ida
Jussing, Emma
Han, Jinming
Goos, Jeroen A. C. M.
Siikanen, Jonathan
Kaipe, Helen
Lambert, Mélanie
Harris, Robert A.
Samén, Erik
Carlsten, Mattias
Holmin, Staffan
Tran, Thuy A.
author_sort Friberger, Ida
collection PubMed
description BACKGROUND: There is a need to better characterise cell-based therapies in preclinical models to help facilitate their translation to humans. Long-term high-resolution tracking of the cells in vivo is often impossible due to unreliable methods. Radiolabelling of cells has the advantage of being able to reveal cellular kinetics in vivo over time. This study aimed to optimise the synthesis of the radiotracers [(89)Zr]Zr-oxine (8-hydroxyquinoline) and [(89)Zr]Zr-DFO-NCS (p-SCN-Bn-Deferoxamine) and to perform a direct comparison of the cell labelling efficiency using these radiotracers. PROCEDURES: Several parameters, such as buffers, pH, labelling time and temperature, were investigated to optimise the synthesis of [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS in order to reach a radiochemical conversion (RCC) of >95 % without purification. Radio-instant thin-layer chromatography (iTLC) and radio high-performance liquid chromatography (radio-HPLC) were used to determine the RCC. Cells were labelled with [(89)Zr]Zr-oxine or [(89)Zr]Zr-DFO-NCS. The cellular retention of (89)Zr and the labelling impact was determined by analysing the cellular functions, such as viability, proliferation, phagocytotic ability and phenotypic immunostaining. RESULTS: The optimised synthesis of [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS resulted in straightforward protocols not requiring additional purification. [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS were synthesised with an average RCC of 98.4 % (n = 16) and 98.0 % (n = 13), respectively. Cell labelling efficiencies were 63.9 % (n = 35) and 70.2 % (n = 30), respectively. (89)Zr labelling neither significantly affected the cell viability (cell viability loss was in the range of 1–8 % compared to its corresponding non-labelled cells, P value > 0.05) nor the cells’ proliferation rate. The phenotype of human decidual stromal cells (hDSC) and phagocytic function of rat bone-marrow-derived macrophages (rMac) was somewhat affected by radiolabelling. CONCLUSIONS: Our study demonstrates that [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS are equally effective in cell labelling. However, [(89)Zr]Zr-oxine was superior to [(89)Zr]Zr-DFO-NCS with regard to long-term stability, cellular retention, minimal variation between cell types and cell labelling efficiency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01622-z.
format Online
Article
Text
id pubmed-8578071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85780712021-11-15 Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications Friberger, Ida Jussing, Emma Han, Jinming Goos, Jeroen A. C. M. Siikanen, Jonathan Kaipe, Helen Lambert, Mélanie Harris, Robert A. Samén, Erik Carlsten, Mattias Holmin, Staffan Tran, Thuy A. Mol Imaging Biol Research Article BACKGROUND: There is a need to better characterise cell-based therapies in preclinical models to help facilitate their translation to humans. Long-term high-resolution tracking of the cells in vivo is often impossible due to unreliable methods. Radiolabelling of cells has the advantage of being able to reveal cellular kinetics in vivo over time. This study aimed to optimise the synthesis of the radiotracers [(89)Zr]Zr-oxine (8-hydroxyquinoline) and [(89)Zr]Zr-DFO-NCS (p-SCN-Bn-Deferoxamine) and to perform a direct comparison of the cell labelling efficiency using these radiotracers. PROCEDURES: Several parameters, such as buffers, pH, labelling time and temperature, were investigated to optimise the synthesis of [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS in order to reach a radiochemical conversion (RCC) of >95 % without purification. Radio-instant thin-layer chromatography (iTLC) and radio high-performance liquid chromatography (radio-HPLC) were used to determine the RCC. Cells were labelled with [(89)Zr]Zr-oxine or [(89)Zr]Zr-DFO-NCS. The cellular retention of (89)Zr and the labelling impact was determined by analysing the cellular functions, such as viability, proliferation, phagocytotic ability and phenotypic immunostaining. RESULTS: The optimised synthesis of [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS resulted in straightforward protocols not requiring additional purification. [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS were synthesised with an average RCC of 98.4 % (n = 16) and 98.0 % (n = 13), respectively. Cell labelling efficiencies were 63.9 % (n = 35) and 70.2 % (n = 30), respectively. (89)Zr labelling neither significantly affected the cell viability (cell viability loss was in the range of 1–8 % compared to its corresponding non-labelled cells, P value > 0.05) nor the cells’ proliferation rate. The phenotype of human decidual stromal cells (hDSC) and phagocytic function of rat bone-marrow-derived macrophages (rMac) was somewhat affected by radiolabelling. CONCLUSIONS: Our study demonstrates that [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS are equally effective in cell labelling. However, [(89)Zr]Zr-oxine was superior to [(89)Zr]Zr-DFO-NCS with regard to long-term stability, cellular retention, minimal variation between cell types and cell labelling efficiency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01622-z. Springer International Publishing 2021-07-06 2021 /pmc/articles/PMC8578071/ /pubmed/34231103 http://dx.doi.org/10.1007/s11307-021-01622-z Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Friberger, Ida
Jussing, Emma
Han, Jinming
Goos, Jeroen A. C. M.
Siikanen, Jonathan
Kaipe, Helen
Lambert, Mélanie
Harris, Robert A.
Samén, Erik
Carlsten, Mattias
Holmin, Staffan
Tran, Thuy A.
Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title_full Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title_fullStr Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title_full_unstemmed Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title_short Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
title_sort optimisation of the synthesis and cell labelling conditions for [(89)zr]zr-oxine and [(89)zr]zr-dfo-ncs: a direct in vitro comparison in cell types with distinct therapeutic applications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578071/
https://www.ncbi.nlm.nih.gov/pubmed/34231103
http://dx.doi.org/10.1007/s11307-021-01622-z
work_keys_str_mv AT fribergerida optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT jussingemma optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT hanjinming optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT goosjeroenacm optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT siikanenjonathan optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT kaipehelen optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT lambertmelanie optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT harrisroberta optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT samenerik optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT carlstenmattias optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT holminstaffan optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications
AT tranthuya optimisationofthesynthesisandcelllabellingconditionsfor89zrzroxineand89zrzrdfoncsadirectinvitrocomparisonincelltypeswithdistincttherapeuticapplications